卡纳比内罗尔在阿尔茨海默病的体外模型中预防了内质网膜和线粒体功能障碍:基于网络的转录组分析
Luigi Chiricosta1, Aurelio Minuti1, Agnese Gugliandolo1
1IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.
Cells
|June 26, 2024
概括
在细胞模型中,大麻素 (CBNR) 显示出对阿尔茨海默病 (AD) 的神经保护作用. 这种化合物可以防止细胞损失并恢复线粒体和内分泌网膜功能,为AD预防提供了潜在的新策略.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种常见的痴呆症,其特点是粉样斑块,神经纤维状结和细胞功能障碍.
- 目前对阿尔茨海默病的治疗方法有限,这突显出需要新的治疗和预防策略.
- 大麻素正在研究它们在神经退行性疾病中的潜在神经保护性质.
研究的目的:
- 在体外阿尔茨海默氏病模型中评估大麻素 (CBNR) 的神经保护潜力.
- 通过下一代测序来研究CBNR影响背后的分子机制.
主要方法:
- 使用差异化SH-SY5Y细胞利用阿尔茨海默病的体外细胞模型.
- 作为AD模型的预处理,给予的卡纳比内罗尔 (CBNR).
- 通过下一代测序进行基于网络的转录组分析,以识别基因表达变化.
主要成果:
- 在AD模型中,CBNR预处理显著抵消了由β-粉样蛋白 (Aβ) 诱导的细胞活力丧失.
- 转录组分析显示,CBNR恢复了正常的线粒体和内分泌网膜功能.
- 通过CBNR调节的关键基因参与了氧化酸化,蛋白质折叠/降解以及葡萄糖/脂质代谢.
结论:
- 大麻素 (CBNR) 在体外AD模型中显示出显著的神经保护作用.
- CBNR的机制涉及恢复与能量代谢和蛋白质平衡相关的细胞功能.
- 这些发现表明CBNR是预防阿尔茨海默病相关功能障碍的潜在治疗剂.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.卡纳比内罗尔 (Cannabinerol) 是一种可怕的药物.细胞内膜网膜的内oplasmic网膜.线粒体中的线粒体.网络分析 网络分析植物大麻素 (phytocannabinoids) 是一种植物性大麻素.转录基因分析更多相关视频
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
10.7K
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.0K
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
